Yanan Zhu
Stock Analyst at Wells Fargo
(0.59)
# 3,808
Out of 4,734 analysts
60
Total ratings
21.74%
Success rate
-18.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Overweight | $70 → $60 | $9.50 | +531.58% | 3 | Jan 10, 2025 | |
| AFMD Affimed | Maintains: Overweight | $20 → $15 | $1.15 | +1,204.35% | 6 | Dec 12, 2024 | |
| EDIT Editas Medicine | Downgrades: Equal-Weight | $7 → $4 | $1.22 | +227.87% | 6 | Dec 11, 2024 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $17 → $4 | $1.20 | +233.33% | 4 | Nov 12, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $77 | $31.43 | +144.99% | 2 | Nov 7, 2024 | |
| BLUE bluebird bio | Maintains: Equal-Weight | $60 → $40 | $8.35 | +379.04% | 7 | Sep 25, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Overweight | $35 → $40 | $20.62 | +93.99% | 2 | May 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $70 → $65 | $40.53 | +60.38% | 1 | May 9, 2024 | |
| ENGN enGene Holdings | Initiates: Overweight | $30 | $7.14 | +320.17% | 1 | Apr 22, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $45 → $58 | $16.79 | +245.44% | 5 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $2.61 | +857.85% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $5.91 | +323.01% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $28.92 | +72.89% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $14 | $5.07 | +176.13% | 1 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $1.27 | +293.70% | 2 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $1.09 | +266.97% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $1.80 | +24,900.00% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $8 | $2.22 | +260.36% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $105 | $23.44 | +347.95% | 2 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $1.53 | +553.59% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1.5 → $3 | $0.58 | +417.33% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $34 → $24 | $14.05 | +70.82% | 1 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $640.52 | -49.10% | 1 | Feb 2, 2021 |
Intellia Therapeutics
Jan 10, 2025
Maintains: Overweight
Price Target: $70 → $60
Current: $9.50
Upside: +531.58%
Affimed
Dec 12, 2024
Maintains: Overweight
Price Target: $20 → $15
Current: $1.15
Upside: +1,204.35%
Editas Medicine
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $1.22
Upside: +227.87%
RAPT Therapeutics
Nov 12, 2024
Maintains: Overweight
Price Target: $17 → $4
Current: $1.20
Upside: +233.33%
Ionis Pharmaceuticals
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $31.43
Upside: +144.99%
bluebird bio
Sep 25, 2024
Maintains: Equal-Weight
Price Target: $60 → $40
Current: $8.35
Upside: +379.04%
Spyre Therapeutics
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $20.62
Upside: +93.99%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $40.53
Upside: +60.38%
enGene Holdings
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $7.14
Upside: +320.17%
Arcturus Therapeutics Holdings
Mar 8, 2024
Maintains: Overweight
Price Target: $45 → $58
Current: $16.79
Upside: +245.44%
Mar 5, 2024
Initiates: Overweight
Price Target: $25
Current: $2.61
Upside: +857.85%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $5.91
Upside: +323.01%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $28.92
Upside: +72.89%
Jan 2, 2024
Upgrades: Overweight
Price Target: $9 → $14
Current: $5.07
Upside: +176.13%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.27
Upside: +293.70%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $1.09
Upside: +266.97%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $1.80
Upside: +24,900.00%
Mar 27, 2023
Assumes: Overweight
Price Target: $8
Current: $2.22
Upside: +260.36%
Mar 1, 2023
Maintains: Overweight
Price Target: $125 → $105
Current: $23.44
Upside: +347.95%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $1.53
Upside: +553.59%
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $1.5 → $3
Current: $0.58
Upside: +417.33%
Aug 9, 2022
Maintains: Equal-Weight
Price Target: $34 → $24
Current: $14.05
Upside: +70.82%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $640.52
Upside: -49.10%